Sir Christopher Evans, the famous British biotechnology entrepreneur, is about to land $ 50 million (37 million pounds sterling) for a developer of a new portfolio of cancer treatment.
Sky News has learned that Sir Christopher, whose previous companies have included Biovex and Chiroscience, is at the advanced stages of the capital security for Pharma Ellipses.
City sources have said that investors in the Middle East and Asia have temporarily agreed to provide most of the new funding, which should be an assessment of around $ 800 million (592 million pounds Sterling).
Capital injection should be the last collection of funds of this type before Sir Christopher seeks a first public offer for Pharma Ellipses, with Hong Kong the most likely place of rating.
The emphasis on Ellipses on oncology has previously attracted investments by eminent contributors, in particular the investment vehicle of Sir Tom Hunter, West Coast Capital.
The members of the board of directors of the company based in London include a executive in Mubadala, the Sovereign Heritage Fund for Abu Dhabi.
In December, he announced the launch of a clinical water trial program.
“This enormous commitment led us to the point where our achievements can be brought to the potential benefit of patients with water,” said Sir Christopher at the time.
“In many ways, we can now bring hope and innovative therapy to people with water and also allow health professionals to collaborate and share research.”
An ellipses spokesperson refused to comment on fundraising.